|
|
2215, Bridgepointe Parkway, Suite 200
San Mateo, CA 94404 USA
phone:650.358.3300
fax:650.649.1798
|
|
| Symbol |
NGSX |
| Exchange |
NASDAQ |
| Founded |
1998 |
| Employees |
|
|
|
| www.neurogesx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals for neuropathic pain treatment . |
|
| Management |
| Anthony DiTonno, President & Chief Executive Officer; Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer; Jeffrey Tobias, M.D., Executive Vice President, Research and Development and Chief Medical Officer; Keith Bley, Ph.D, Senior Vice President, Nonclinical Research & Development; Michael Markels, Senior Vice President, Commercial and Business Development |
| |
|
|
|
|
|
|
|
| Keywords |
| qutenza, capsaicin, neuropathic, therapeutic, dermal |
|
|
|
| Description |
|
NeurogesX is a neuroscience-based specialty pharmaceutical company developing products for the treatment of pain. |
|
| Products / Services |
NeurogesX is currently investigating the effects of applying a pure, high-concentration form of synthetic capsaicin, known as trans-capsaicin, directly to the site of pain via a rapid-delivery dermal application system. Its product candidate, NGX-4010, may provide months of relief from a single application.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
